# Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively

> **NCT05568719** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 173 (estimated)

## Conditions studied

- Hemophilia A
- Hemophilia B

## Interventions

- **DIAGNOSTIC_TEST:** Testing of hepatic AAV Vector integration

## Key facts

- **NCT ID:** NCT05568719
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-28
- **Primary completion:** 2040-02-25
- **Final completion:** 2040-02-25
- **Target enrollment:** 173 (ESTIMATED)
- **Last updated:** 2026-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05568719

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05568719, "Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively". Retrieved via AI Analytics 2026-09-22 from https://api.ai-analytics.org/clinical/NCT05568719. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*